RAPT Therapeutics (RAPT) Accumulated Expenses (2020 - 2024)
Historic Accumulated Expenses for Therapeutics (RAPT) over the last 5 years, with Q3 2024 value amounting to $6.4 million.
- Therapeutics' Accumulated Expenses fell 5465.31% to $6.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $6.4 million, marking a year-over-year decrease of 5465.31%. This contributed to the annual value of $14.1 million for FY2023, which is 6292.74% up from last year.
- Latest data reveals that Therapeutics reported Accumulated Expenses of $6.4 million as of Q3 2024, which was down 5465.31% from $9.5 million recorded in Q2 2024.
- In the past 5 years, Therapeutics' Accumulated Expenses registered a high of $14.1 million during Q3 2023, and its lowest value of $3.8 million during Q1 2020.
- Moreover, its 5-year median value for Accumulated Expenses was $7.5 million (2022), whereas its average is $7.9 million.
- In the last 5 years, Therapeutics' Accumulated Expenses surged by 8233.09% in 2022 and then plummeted by 5465.31% in 2024.
- Therapeutics' Accumulated Expenses (Quarter) stood at $4.9 million in 2020, then grew by 28.19% to $6.3 million in 2021, then skyrocketed by 36.83% to $8.7 million in 2022, then surged by 62.93% to $14.1 million in 2023, then crashed by 54.63% to $6.4 million in 2024.
- Its Accumulated Expenses was $6.4 million in Q3 2024, compared to $9.5 million in Q2 2024 and $11.8 million in Q1 2024.